Home | Find A Doctor | Contact Us

 

A Phase III Randomized Study of Oral Sapacitabine In Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia


Principal Investigator: Sanford Kempin, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
Previous clinical studies suggest sapacitabine and decitabine are well suited in providing anti-leukemic activities for the treatment goal of controlling the disease and improving tumor-related signs/symptoms in elderly patients suffering from AML.

The primary objective of this study is to compare the overall survival between those randomized to the group receiving sapacitabine and decitabine, versus those receiving decitabine alone.


Eligibility and Treatment Plan:
• Age = 70 years
• Diagnosis of acute myeloid leukemia (AML), and for whom the treatment of choice is low-intensity therapy by investigator assessment or who are not willing to receive intensive induction therapy recommended by investigator
• Must be able to swallow capsules

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System